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Abstract 
 
Background 
In randomized controlled trials, novel oral anticoagulants (NOAC) demonstrated non-
inferiority to Vitamin K antagonists (VKA) in patients who spent limited time in therapeutic 
range (TTR). In real-life patients TTR is known to vary significantly across countries and 
healthcare settings.  
 
Objective 
We aim to evaluate the quality of VKA treatment in Swiss primary care (PC) by comparing 
patients’ median TTR to levels achieved in the phase III NOAC trials RE-LY, ROCKET-AF, 
ARISTOTLE, and ENGAGE-AF-TIMI 48. Patient characteristics affecting TTR control shall 
be estimated.  
 
Methods 
This is a retrospective longitudinal study in Swiss PC patients receiving VKA for ≥6 months. 
We identified patients from the PC research database «FIRE» and calculated TTR according 
to Rosendaal’s formula. Comparative data from NOAC trials were retrieved from medical 
literature. Linear regression models were used to assess predictors of TTR. 
 
Results 
PC encounters of 215 patients were analyzed. Like in the NOAC trials, median observation 
period was 2.2 years, but patients were older (67.9% vs. 38% ≥75 years) and differed in 
terms of concomitant diseases and drugs. Median TTR was 75% (65% in the NOAC trials). 
Female sex was independently associated with a lower TTR and significantly modified by 
increasing age. 
  
Conclusion 
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Practitioners should consider that patients in NOAC trials are only partly representative of PC 
patients, particularly in terms of TTR control. Only a minority of the observed patients would 
require a therapy switch to NOACs due to inadequate TTR. Further research is needed in 
order to identify specific features of care management that are associated with these 
outcomes. 
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Introduction 
Optimal management of long-term anticoagulant treatment for the prevention and treatment 
of thrombosis, cardiovascular and cerebrovascular events is subject of increasing interest, 
mainly due to the availability of non-Vitamin K antagonist oral anticoagulants (NOACs). The 
introduction of NOACs questioned the usefulness of the Vitamin K antagonists (VKA), whose 
efficacy and safety are known to depend largely on the quality of anticoagulation control. 
Reports on patients’ time spent in therapeutic range (TTR) of international normalized ratio 
(INR) level in daily practice of various countries suggest that the quality of anticoagulation 
control with VKA is poor, especially in primary care settings [1]. Reported TTR commonly 
ranges between 52% and 64%, but also lower values (29%) have been observed [2-24].  
Specialized anticoagulation clinics (ACCs) and patients’ self-monitoring tend to show better 
outcomes. However, in light of the high prevalence of patients in need of anticoagulant 
treatment, it does not seem feasible that solely ACCs could take care of these patients, and 
self-monitoring may not be feasible for everyone [15-22,25-29].  
NOACs could represent a solution to this dilemma, since their pharmacologic properties 
simplify the administration and do not require monitoring [30]. However, the body of evidence 
in favor of NOACs is of questionable significance for the primary care setting since it is 
predominantly based on phase III randomized controlled trials (RCTs) with non-inferiority 
design and carefully selected patient populations treated in specialized centres for atrial 
fibrillation [31-35]. These approval studies show non-inferiority of NOACs as compared to the 
VKA agent warfarin, whereby patients under warfarin treatment spent on average (median) 
65% of the follow-up time within the therapeutic range of INR 2–3 [35]. Owing to important 
differences in study design and a lack of head-to-head trials, whether or not the different 
NOAC agents are equivalent with regards to efficacy and safety has not been verified yet 
[36-40]. Data on the effectiveness of the agents (i.e. the extent to which the agents achieve 
their intended effect in the usual clinical setting) are derived from observational studies, not 
from randomized controlled trials, and often lack information on the TTR of patients under 
VKA treatment [41-47]. So, it remains unclear if these studies compared NOAC performance 
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to high or low quality VKA treatments. The validity of these comparisons is therefore limited. 
As far as the NOAC agent dabigatran is concerned, advantages over warfarin were only 
seen in study centres where TTR was less than 72% [48]. 
By contrast, there are also examples of high quality TTR control in daily practice. Previous 
reports from Sweden and the Netherlands documented TTR benchmarks as high as 76% 
and 81%, respectively [49-51]. Moreover, a sub-analysis of the ROCKET AF trial revealed 
global geographic region as being the strongest predictor of patients’ individual TTR 
independent of patients’ characteristics such as age and comorbidities [52]. This finding is 
likely to reflect different structures of care and support systems to manage warfarin and 
different regional barriers to frequent INR testing and warfarin dose changes. Under daily 
practice conditions – outside of clinical trials – local differences also include the use of VKA 
agents other than warfarin (e.g. phenprocoumon, fluindione, acenocoumarol) that differ 
considerably regarding their half-lives, further affecting the comparability of local settings 
[18,53,54].  
Therefore, it seems unjustified to extrapolate findings made under study conditions or in 
foreign healthcare settings and to define a one-size-fits-all decision on first-line anticoagulant 
agents and ideal provision of care services without discussing the current standard of TTR 
control in specific care settings. 
It is the aim of our study to contribute data on TTR control achieved in Swiss primary care 
practices to the discussion. As in many other countries, long-term anticoagulant therapy in 
Switzerland is mainly a task of general practitioners (GPs) [55]. Available VKA agents are 
phenprocoumon and acenocoumarol. Most frequently, phenprocoumon is used. INR 
monitoring is usually performed using a point-of-care device in order to adjust VKA dosage 
prescription during the same consultation if necessary. To date, the average TTR achieved in 
this setting is unknown, and it is unclear whether the patient populations of the RCTs are 
representative of Swiss primary care patients. We aim: 
1) to evaluate the stability of anticoagulant treatment in Swiss primary care expressed as 
patients’ average TTR of INR 2−3 as compared to the TTR levels achieved in the warfarin 
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arms of NOAC approval studies, RE-LY, ROCKET-AF, ARISTOTLE, and ENGAGE-AF-TIMI 
48 [31-34]; 
2) to evaluate the characteristics of patients who receive long-term anticoagulant 
treatment with VKAs for ≥6 months in Swiss primary care; 
3) to compare these characteristics to baseline characteristics of intention-to-treat (ITT) 
populations included in the abovementioned RCTs; and 
4) to assess the impact of patient characteristics known to affect anticoagulation control 
with VKA measured by TTR; 
 
 
Material and Methods 
In this retrospective longitudinal study, we calculated the TTR of Swiss primary care patients 
receiving long-term anticoagulant treatment with VKAs for ≥6 months without interruption 
based on recorded results of INR tests according to Rosendaal’s formula [56]. The combined 
ITT population included in the NOAC approval studies RE-LY, ROCKET-AF, ARISTOTLE, 
and ENGAGE-AF-TIMI 48 served as a comparator to our study population. We will 
subsequently refer to this population as the NOAC RCT population. 
 
FIRE database 
Eligible patients were identified from the primary care research database FIRE (Family 
medicine ICPC Research using Electronic medical records) receiving long-term 
anticoagulant treatment with VKAs for ≥6 months. The FIRE database is the core of an 
ongoing health services research project at the Institute of Primary Care at the University and 
University Hospital of Zurich, Switzerland. Details about the project, the data structure and 
the validation of the database were reported previously [57,58]. In short, the database 
established in 2009 contains information on all physician-patient contacts in participating 
primary care practices around Switzerland. Data are extracted from routinely used electronic 
medical records, fully anonymized and aggregated by individual consultation dates and 
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randomly generated, de-identifiable but unique patient ID numbers. The dataset covers 
patients’ age, sex, reasons for encounter according to the ICPC-2 classification (International 
Classification of Primary Care 2) [59], vital signs, laboratory test results as well as type and 
dosage of prescribed medication according to Anatomical Therapeutic Chemical/Defined 
Daily Dose Classification (ATC/DDD) coding established by the WHO [60]. According to 
current Swiss law on human research retrospective analysis of anonymously collected 
medical routine data requires no approval by regional ethics committees [61]. 
 
Patient population 
All patients with INR tests recorded between May 2009 and January 2015 were eligible and 
included based on the following criteria: 
- prescribed VKA treatment for at least 6 months (this criterion would exclude patients with 
VKA treatment due to a first event of deep vein thrombosis and time-limited risk of 
thromboembolic disease) 
- no prescription of heparin agents during VKA treatment period (this criterion would 
exclude patients with periprocedural interruption of VKA treatment and heparin bridging). 
Patients’ baseline characteristics were directly obtained from the FIRE database or derived 
from the available dataset as follows: Indication for anticoagulant treatment was derived from 
the ICPC-2 codes assigned to the patient during VKA treatment; Presence of concomitant 
chronic conditions were derived both from ICPC-2 codes and pharmaceutical cost groups 
based on ATC/DDD coding according to the established algorithms of O’Halloran et al. and 
Lamers et al., respectively [62,63]. This approach has previously been validated for the FIRE 
database [58,64]; All drugs prescribed for at least 6 months were considered to be long-term 
medication and counted as concomitant drugs; CHADS2-Score of stroke risk in patients with 
atrial fibrillation according to ICPC-2 coding was calculated according to Gage, et al. [65]. We 
used the CHADS2-Score instead of the CHA2DS2-VASc-Score for comparison reasons, 
because the NOAC approval studies exclusively reported the CHADS2-Score. Creatinine 
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clearance in ml/min was calculated based on serum creatinine values according to the 
Cockroft-Gault equation [66]. Bleeding events were not registered in the database. 
 
Comparative studies 
Baseline characteristics of the NOAC RCT population were extracted from the datasets of 
the RE-LY, ROCKET-AF, ARISTOTLE, and ENGAGE-AF-TIMI 48 studies published in 
medical literature [31-35].  
 
Outcome definitions 
We defined good anticoagulation control as TTR >70%, moderate control as TTR 61−70%, 
poor control as TTR 40−60% and ineffective control as TTR <40% based on guideline 
recommendations and current literature [38,67-74]. 
 
Statistics 
Data are presented as frequencies and percentages, mean and standard deviation (SD) or 
median and interquartile range (IQR), where appropriate. If not indicated otherwise, all 
percentages refer to the total number of included patients. First, correlation of TTR and age, 
sex, overall number of chronic conditions and drugs taken, hypertension, diabetes, 
congestive heart failure, creatinine clearance, CHADS2-scoring, length of observation 
(years), number of physician-patient contacts and number of INR tests was assessed using 
univariable linear regression models. Results are presented as coefficients, 95% confidence 
intervals (CI) and p-values. A p-value <0.1 was considered as statistically significant. In a 
second step, all variables showing a significant impact on TTR in univariable analysis were 
included in a multivariable linear regression model. Subsequently, robustness of the results 
was tested by adding GPs as random variable to the model (mixed model) in order to adjust 
for clustering effects. Then, a p-value <0.05 was considered as statistically significant. All 
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statistical analyses were done in R (version 3.0.2, The R Foundation for Statistical 
Computing, Vienna, Austria). 
 
 
Results 
Consultation data of 670 patients with INR tests recorded between May 2009 and January 
2015 were eligible. Of these, 256 patients received VKA treatment for less than 6 months 
and were thus excluded. Another 199 patients were excluded because of periprocedural 
interruption of VKA treatment and heparin bridging (Flowchart in Fig. 1). 215 patients treated 
by 12 physicians fulfilled the inclusion criteria and were included in the analysis. Patient 
characteristics are summarized in Table 1. The NOAC RCT population included 71’683 
patients. Of these, 29’272 were allocated to warfarin treatment. 
Our patients were similar to the ITT population included in the NOAC RCTs in terms of length 
of observation (both median 2.2 y), rate of concomitant hypertension (87.9% vs. 88%) and 
CHADS2-scoring (median 2.7 vs. 2.6). Differences were found in terms of sex, age, rate of 
concomitant diabetes mellitus and congestive heart failure, creatinine clearance and number 
of INR tests per year and patient (Table 1). In our study population, more patients were 
female (50.7% vs. 37.5%) and aged 75 years or older (67.9% vs. 38%). The proportion of 
patients with concomitant diagnosis of diabetes mellitus was lower than in the NOAC 
approval studies (18.1% vs. 31%), whereas the proportion of patients with congestive heart 
failure was higher (61.4% vs. 46.5%). In sum, more patients in our study showed a creatinine 
clearance of ≥50 ml/min (84.5% [n=115/136] vs. 81.5%), but unlike in the NOAC approval 
studies, also two (1.5%) patients with creatinine clearance ≤30 ml/min were included. The 
median number of GP encounters within our study population was 14.5 times per year, and 
INR was tested every 6 weeks (median 8 tests per year). The NOAC approval studies 
requested at least monthly follow-up contacts and INR tests in patients receiving warfarin − 
that is a minimum of 12 tests per year.   
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Number of chronic conditions other than those leading to an indication for anticoagulant 
treatment, number of additional drugs taken and liver function parameters (aspartate 
transferase, AST; alanine transferase, ALT) of the NOAC RCT population have not been 
publicly published. In our study population, the mean number of concomitant chronic 
conditions was 5.3 (SD 2.3). Apart from VKA, patients took 7 (SD 4.2) concomitant drugs. 
Mean values of both AST and ALT were within the reference ranges as specified by the 
International Federation of Clinical Chemistry and Laboratory Medicine [75], but one patient 
(n=1/101, 1%) showed values >2 times the upper limit of normal (ULN). Such values 
constituted an exclusion criterion in the RELY, ARISTOTLE and ENGAGE-AF-TIMI 48 trials 
[76-78]. No patient showed values >3 times ULN (exclusion criterion in the ROCKET-AF trial 
[34]).   
 
Time in therapeutic range (TTR) 
Individual median INR in our study population was 2.4. Patients spent median 75% of 
treatment time within the therapeutic range of INR 2−3. Median TTR in the warfarin arm of 
the NOAC RCTs was 65% (Table 2). In our study, 60.9% of patients reached or exceeded 
this threshold (TTR ≥65%). The majority of our patients showed good (55.8% with TTR>70%) 
or moderate (9.8% with TTR 61−70%) anticoagulation control. Poor and ineffective control 
was found in 20.9% and 13.5%, respectively. The median treatment time in a subtherapeutic 
INR range (INR<2) was 10.1% (IQR 1.8−29.6%) and the median treatment time above the 
therapeutic range (INR>3) was 5.5% (IQR 0−17.2%). 
Univariable linear regression analysis demonstrated significant associations between lower 
TTR and patients’ age, sex, number of concomitant chronic conditions and diagnosis of 
congestive heart failure, and significant associations between higher TTR and length of 
observation and number of INR tests (Table 3). In the subsequently performed multivariable 
regression analysis, sex remained a significant predictor of TTR and was significantly 
modified by age (p=0.0059 for the interaction term sex*age). This result remained unchanged 
when controlled for a cluster effect originating from GPs. Age was not an independent 
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predictor of TTR, but a significant interaction between age and sex was found. A cluster 
effect was not present (Table 4).  
 
 
Discussion 
In this study, we examined the quality of anticoagulant treatment with VKA in Swiss primary 
care patients, measured by individual TTR. It is the first study of this kind in Switzerland and 
showed a remarkably high level of TTR control. Median TTR was 75% exceeding not only 
the median TTR level achieved in the NOAC RCTs but also TTR levels reported from daily 
practice settings in other Western countries, and is comparable to the data on 
anticoagulation self-management in Switzerland [79]. This finding ranks Switzerland with the 
best performing countries, Sweden and the Netherlands, which had previously reported TTR 
benchmarks of 76% and 81% [49-51]. 
Previous estimations of the quality of VKA treatment control in Switzerland did not forecast 
our finding. In the absence of real life data, these estimations were made based on regional 
analyses of NOAC RCTs. They suggested that TTR levels achieved in Swiss patients would 
be of minor quality. In the RE-LY trial, for instance, Swiss study centres showed a mean 
centre TTR of 68% [48]. In the ROCKET-AF trial, mean individual TTR of Swiss patients was 
below the average baseline TTR of Western Europe (63.2%) [52]. The impact of such 
estimations must not be underestimated. According to current European guidelines, patients 
with a TTR below 70% should receive NOAC instead of VKA [38]. Based on the 
abovementioned estimations of TTR levels achieved in the Swiss healthcare setting, one 
could conclude that the majority of Swiss patients under VKA treatment had to be switched to 
NOAC and patients should generally be started on NOAC in order to avoid a few promising 
but strenuous VKA therapy initiation [71]. Not only would large quantities of therapy changes 
challenge patients and clinicians, but the mass of new NOAC prescription would also have 
relevant economic influence on the country’s obligatory health insurance system covering 
anticoagulant treatment. It has been shown that NOACs can be cost-effective in specific 
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settings despite higher pharmaceutical costs, because overall costs for anticoagulation 
related outpatient visits and hospitalizations were reduced compared to warfarin treatment 
[80-84]. However, just like clinical outcomes, also cost-efficiency estimations have been 
demonstrated to depend on TTR levels achieved in the VKA group [85,86].  
Our findings, now, reduce concerns about the magnitude of the patient population requiring 
therapy changes by suggesting that the majority of Swiss patients maintain stable TTR levels 
and would not require therapy changes. Moreover, regression analysis indicated that TTR 
was independent of a wide range of patient characteristics. We conclude that all GPs were 
apparently able to control TTR irrespective of confounding influences.  
 
 
Strength and limitations 
Of course, it needs to be acknowledged that our study sample was small compared to the 
overall number of patients included in the NOAC RCTs or in foreign observation registries 
[5,8,24]. One might further argue that there are a number of potential confounders impacting 
on TTR that we did not include in our regression models. In response to these claims, it is to 
note that the strength of our study is not only the use of local data, but also setting-specific 
data. Two aspects are to note: 
1) All figures must be seen in proportion to the limited availability of regional data. 
Numbers of Swiss patients recruited in the RE-LY and ARISTOTLE trials are not 
publicly published, but it is known that TTR information on Swiss patients in the 
ROCKET-AF study were derived from only four Swiss patients [87]. In the ENGAGE-
AF-TIMI 48 trial, zero Swiss patients received warfarin [88]. In comparison, we present 
results from 215 patients. 
2) It was not the aim of this study to newly identify all potentially imaginable determinants 
of TTR control. We assessed the impact of those baseline characteristics in our dataset 
that are known to affect anticoagulation control in order to control for potential 
confounders. 
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Thus, our results should not be generalized to other health care settings nor be understood 
in a way that TTR control is always independent of patient characteristics. It is widely verified 
that patient characteristics such as concomitant diseases and female sex – also significant in 
our study – can act as significant predictors of TTR [2,8,12,51,71]. Explanations for these 
observations are, however, scarce. It is likely that some of the previously reported 
associations of TTR and patient characteristics are random effects due to multiple testing in 
very large data samples. On the other hand, it may also be well assumed that the previously 
observed effects actually reflect underlying differences of patients’ health literacy, self-
management resources, adherence to medical advice or access to medical care, in brief 
sociodemographic and infrastructural features of the healthcare setting [89].  
The results of our mixed models regression analysis indicate that features of the Swiss 
primary care setting, other than number of consultations and INR tests, might overrule the 
effect of patient characteristics on TTR control and ensure stable TTR maintenance. For 
instance, the point-of-care testing in GP practices is an important feature that is known to 
influence TTR [90,91]. It will be a task of future research to examine this hypothesis with 
adequate methods.  
It was the aim of our study to evaluate TTR control in the circumscribed setting of Swiss 
primary care and call one-size-fits-all recommendations of first-line anticoagulant treatment 
into question. Indeed, our results highlight the importance of local and setting-specific TTR 
assessments by demonstrating that real-life TTR outcomes in individual health care settings 
may deviate from expected values derived from RCTs or observation studies in foreign 
health care systems. It is important to note that our patients achieved better TTR results than 
the NOAC control group population, even though our patients were remarkably older than the 
NOAC ITT population and presented a lot of concomitant chronic diseases and 
polypharmacy. This raises concerns about the «gold standard» of VKA treatment that served 
as a reference in the NOAC RCTs and should be taken into account when deriving practice 
guidelines from RCT results. Initial observations indicating that patients enrolled in NOAC 
RCTs are only partly representative of patients with atrial fibrillation in clinical practice were 
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made in Korea [92]. Our study confirms these findings now within a European context, but 
unlike the Korean study, we found that when TTR is considered, fewer patients than 
expected would require NOAC therapy instead of VKA.  
Of course, TTR should not be the only basis of decision-making. Bleeding events are another 
reason for switching to NOACs, but were out of scope of this study. None of the observed 
patients stopped VKA treatment because of bleeding events, but information on patients was 
limited to GPs medical record entries. Thus, occurrence of bleeding events leading to 
consultation of other healthcare providers cannot be ruled out entirely. Bleeding prevalence 
in Swiss VKA patients should be examined in a next step. 
The burden of treatment should also be considered when selecting anticoagulant agents, 
and in many situations the ease of use will speak in favor of NOACs. Nevertheless, it must 
be acknowledged that periodical INR monitoring required under VKA treatment imposes not 
necessarily a burden for patients and primary physicians. A recent study suggested that it 
could also enhance patient-physician relation and therapy adherence and offer opportunities 
for the physician to provide additional care to patients, such as adjusting the dosage of 
antihypertensive drugs, giving smoking cessation advice or treating high cholesterol [93]. Our 
findings now show that concomitant comprehensive care for other conditions does not impair 
physicians’ resources in controlling INR and ensuring high quality TTR control. This is of 
particular relevance for daily practice in primary care worldwide, given the high prevalence of 
multimorbidity in primary care patients [94]. 
As long as published data on NOAC use in elderly, multimorbid patient populations is scarce, 
general recommendations of NOACs as first-line treatment in such patients should be taken 
with caution. In the meantime, physicians should instead tailor anticoagulation management 
according to the individual needs of their patients with regard to the heterogeneity, age, 
multimorbidity and risk profile of patients in primary care settings. Our findings show that high 
quality TTR can be achieved even in such vulnerable patients. 
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Conclusion 
Choice of anticoagulant agents is a complex medical decision and should be taken in 
comprehensive view of patients’ individual risk-benefit profile. Practitioners should consider 
that the non-inferiority of NOACs has been proven in RCTs which enrolled patients who are 
only partly representative of patients in primary care, particularly in terms of TTR 
maintenance when receiving VKA treatment. The observed majority of our patients would not 
require an immediate switch to NOACs due to low-quality TTR. Further research is needed in 
order to identify specific features of care management that are associated with these 
outcomes, since most patients’ characteristics were insignificant predictors of TTR. 
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Fig. 1: Flow chart of study sample selection – patients with VKA therapy 
670 eligible primary care patients 
from FIRE database with 
recorded INR results 
414 (61.8%) patients with 
prescribed VKA treatment 
for ≥6 month 
256 (38.2%) patients with 
prescribed VKA treatment 
for <6 month 
TTR Analysis:
215 (51.9%) patients without 
intermittent use of heparins
199 (48.1%) patients with 
intermittent use of heparins 
Exclusion
Exclusion
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Tab. 1: Baseline characteristics of included patients in comparison to the intention-to-treat 
population of the NOAC approval studies 
Baseline characteristics 
Included patients 
(n=215) 
Combined ITT 
population included 
in the RE-LY, 
ROCKET AF, 
ARISTOTLE, and 
ENGAGE AF–TIMI 48 
trials (n=71'683)‡ 
          
Gender         
Male 106 49.3%   62.5% 
Female 109 50.7%   37.5% 
Age (y) 
    mean, SD 77.2 11.8 71.6 
  Patients ≥75 y 146 67.9% 
 
38% 
Indication for anticoagulant treatment         
Non-valvular atrial fibrillation 104 48.4% 71'683 100% 
Pulmonary embolism 15 7.0% 0 0% 
Recurrent deep vein thrombosis 11 5.1% 0 0% 
Missing information 82 38.1% 0 0% 
Chronic conditions 
    Patients with ≥1 chronic condition 214 99.5% NA NA 
Number of chronic conditions (mean, SD) 5.3 2.3 NA NA 
Hypertension (n,%) 189 87.9% 
 
88% 
Diabetes mellitus (n,%) 39 18.1% 
 
31% 
Congestive heart failure (n,%) 132 61.4% 
 
46.5% 
Concomitant long-term medication         
Patients with ≥1 concomitant drugs 207 96.3% NA NA 
Number of concomitant drugs (mean, SD) 7 4.2 NA NA 
Observation period (y) 
    median, IQR 2.2 1.5-4.1 2.2 
 Number of contacts per year         
median, IQR 14.5 9.4-23.5 NA NA 
Number of INR tests per year 
    median, IQR 8.0 5.2-11.8 12 (at least 1/month) 
CHAD2-Score of stroke risk*         
mean, SD 2.7 1.2 2.6 1.0 
Score (n,%)         
0-1 9 8.7%   17% 
2 31 29.8%   34% 
3-6 64 61.5%   49% 
Creatinine clearance (ml/min)** 
    GFR (mean, SD) 73.4 22.9 NA NA 
≥50 ml/min 115 84.6% 
 
81% 
<50 ml/min (n,%) 21 15.4% 
 
19% 
≤30 ml/min (n,%) 2 1.5% exclusion criterion 
Liver function enzymes (U/l)***         
AST (mean, SD) 20.4 7.7 NA NA 
ALT (mean, SD) 19.3 14.3 NA NA 
>2 ULN (n,%) 1 1.0% exclusion criterion 
     * data calculated from n=104 (48.4%) of included patients with ICPC diagnosis of Atrial Fibrillation 
**  data available from n=136 (63.3%) of included patients 
  *** data available from n=101 (47.0%) of included patients 
  ‡ data calculated from published data in [33];  
ITT: intention-to-treat; SD: standard deviation; IQR: interquartile range; INR: international normalized ratio; GFR: 
glomerular filtration rate; AST: aspartate transferase; ALT: alanine transferase; ULN: upper limit of normal 
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Tab. 2: INR and Time in therapeutic range (TTR) achieved in the study population in 
comparison to the intention-to-treat population of the NOAC approval studies 
 
  
Study population (n=215) 
Combined ITT 
population receiving 
Warfarin in the RE-
LY, ROCKET AF, 
ARISTOTLE, and 
ENGAGE AF–TIMI 48 
trials (n=29'272)‡ 
Individual median INR (IQR) 2.4 (2.2 − 2.6) NA 
 
NA 
 Individual median TTR (IQR) 75% (53% − 89%) 65% (51% − 76%) 
         ‡ data from [33] 
       INR: international normalized ratio; TTR: time in therapeutic range; IQR: interquartile 
range 
 
Tab. 3: Coefficients and 95%CIs from univariable regression models 
Variable Coefficient CI 95% p-value‡ 
Age -0.005 -0.008 ‒ -0.002 0.0004 * 
Sex (female) -0.138 -0.204 ‒ -0.073 0.0001 * 
Number of chronic conditions -0.016 -0.031 ‒ -0.001 0.0326 * 
Number of concomitant drugs -0.007 -0.015 ‒ 0.001 0.1015 
 Hypertension -0.083 -0.189 ‒ 0.023 0.1265 
 Diabetes mellitus -0.056 -0.144 ‒ 0.033 0.2177 
 Congestive heart failure -0.072 -0.142 ‒ -0.003 0.0426 * 
Glomerular filtration rate (ml/min) 0.000 -0.001 ‒ 0.001 0.9784 
 CHAD2-Score of stroke risk -0.010 -0.065 ‒ 0.046 0.7314 
 Length of obervation (years) 0.028 0.005 ‒ 0.050 0.0155 * 
Number of consultations 0.000 -0.001 ‒ 0.001 0.5543 
 Number of INR tests 0.002 0.000 ‒ 0.004 0.0629 * 
       
‡significance level p<0.1, significant values are marked with an asterisk 
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Tab. 4: Coefficients and 95%CIs from a multivariable regression model (mixed model): 
TTR=age*sex+number of chronic conditions+congestive heart failure+length of 
observation+number of INR tests with GP as random variable 
 
 
Coefficient CI 95% p-value‡ 
Age -4.3E-05 -0.004 ‒ 0.004 0.9824 
 Sex (female) -0.105 -0.173 ‒ -0.038 0.0023 * 
Age*Sex (female) -0.009 -0.015  -0.003 0.0059 * 
Number of chronic conditions -0.013 -0.029 ‒ 0.003 0.1099 
 Congestive heart failure -0.027 -0.102 ‒ 0.048 0.4862 
 Length of obervation (years) 0.012 -0.018 ‒ 0.043 0.4293 
 Number of INR tests 0.002 -0.001 ‒ 0.004 0.2252 
 
 
    
  ‡significance level p<0.05, significant values are marked with an asterisk 
 
 
